In a significant step toward advancing respiratory healthcare, Cipla Limited has established India’s first Sputum Inflammometry Laboratory at the Breathefree Lung Wellness Center (BLWC) in Mumbai. The initiative is expected to strengthen precision-based diagnosis and treatment of chronic respiratory diseases across the country.
The facility was inaugurated by Dr. Parameswaran Nair, an internationally renowned expert and one of the key pioneers of sputum Inflammometry. The launch event was attended by 15 leading pulmonologists and respiratory medicine specialists representing prominent healthcare institutions from across India.
Sputum inflammometry is a specialized diagnostic technique used to measure inflammation within the airways. It helps clinicians better evaluate and manage chronic respiratory disorders, including severe asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis.
Commenting on the development, Dr. Jaideep Gogtay, Global Chief Medical Officer, Cipla Limited, said, “Chronic respiratory diseases are increasingly complex and heterogeneous in nature, making accurate assessment of airway inflammation critical for optimal disease management.”
He further added, “Sputum Inflammometry has transformed the understanding and management of airway diseases globally by enabling clinicians to identify specific inflammatory phenotypes and tailor therapy accordingly. This advanced capability can now play an important role in improving respiratory care and advancing clinical research in India.”
The introduction of this advanced laboratory reflects the growing emphasis on personalized healthcare and innovation in respiratory medicine. Experts believe the facility will support more precise treatment decisions, improve patient outcomes, and contribute to the future of respiratory research in India.
(Logo courtesy: cipla.com)